Autres langues Genome & Company

Actions

A314130

KR7314130006

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
6 560 ^KRW	-2,67 %		-4,93 %	-47,48 %

24/01	Genome & Company annonce les résultats positifs de l'essai clinique de phase 2 sur la combinaison de GEN-001 et Bavencio® ? pour le traitement du cancer gastrique Poster présenté à l'ASCO GI	CI
2023	Genome & Company annonce les résultats positifs de l'analyse intermédiaire de l'essai de phase II Gen-001 Plus Avelumab (Bavencio® ?)	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	24/01
Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	19/05/23
Genome & Company announced that it has received KRW 23 billion in funding from a group of investors	07/04/23
Genome & Company announced that it expects to receive KRW 23 billion in funding from a group of investors	05/04/23
Genome & Company announced that it has received KRW 34.34975035 billion in funding from a group of investors	02/09/22
Genome & Company announced that it expects to receive KRW 34.34975035 billion in funding from a group of investors	18/08/22
Genome and Company Announces Clinical Trial Collaboration with Merck & Co., Inc	04/03/22
Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse	21/09/21
Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index	20/09/21
Genome & Company agreed to acquire a 60% stake in List Biological Laboratories, Inc. for $27 million.	08/09/21
Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study	09/03/21
Genome & Company and Debiopharm Join Forces to Create New Highly Specific Therapies for Cancer Patients	25/02/21
Genome & Company Announces First Patient Dosed in Phase 1/1B Study of GEN-001	27/10/20
Genome & Company announced that it expects to receive KRW 19.99999001 billion in funding from Korea Development Bank, Investment Arm	26/08/20
Scioto Biosciences, Inc. announced that it has received $26.5 million in funding from Genome & Company and other investors	11/08/20
Scioto Biosciences, Inc. announced that it expects to receive $6.50074 million in funding	07/08/20
Genome & Company announced that it has received KRW 4.00002 billion in funding	25/06/20
Genome & Company announced that it expects to receive KRW 4.00002 billion in funding	17/06/20
Genome & Company announced that it has received KRW 3.62991 billion in funding	24/04/20
Genome & Company Receives FDA IND Clearance for GEN-001, its First Anti-Cancer Microbiome Therapeutic	20/04/20

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Genome & Company

Actions

A314130

KR7314130006

Autres langues

Filtres